49 results about "Polymannuronic acid" patented technology

The invention discloses an alginate lyase SHA‑3 gene, the nucleotide sequence of which is shown in SEQ ID NO: 1. The invention constructs a prokaryotic expression vector of the alginate lyase SHA‑3 gene, which can be used in The expression product alginate lyase SHA‑3 was obtained in a short period of time, and it has a wide range of substrate specificity. It can use both polymannuronic acid PolyM and polyguluronic acid PolyG as substrates, and the enzyme activity reaches 12U / mg, is a bifunctional enzyme with broad application prospects, the prokaryotic expression vector and the overall expression system of the present invention are easy to operate, and are convenient for industrial production.

The invention discloses a method for preparing mannuronic acid monomer by degrading polymannuronic acid with sulfuric acid. Bio-Gel P10fine or Bio-Gel P6fine gel permeation chromatography is used to separate and purify the degraded oligosaccharide mixture to obtain 10 oligosaccharide components; use thin layer chromatography (TLC), high performance liquid chromatography (HPLC), mass spectrometry (MS) to analyze different components, and prepare mannuronic acid oligosaccharides with a polymerization degree of 1‑10 monomer. The method of the present invention can prepare mannuronic acid oligosaccharide monomers with a degree of polymerization of 1-10, and the purity reaches more than 95%. At the same time, the method uses sulfuric acid as the degradation condition, and anhydrous calcium carbonate is added after degradation, and after stirring and filtering Sulfate ions can be removed directly to avoid secondary desalination during purification. The method is time-consuming, simple and easy to operate, and can be separated and purified in large quantities with good repeatability.

The invention provides an antithrombotic medicament for intravenous injection. The medicament is a modified acidic polysaccharide consisting of only one monosaccharide and has a structural general formula, wherein R is -CH3 or -CH2-CH(OH)-CH3; R' is -H or -SO3Na; each sugar ring has at least one R' which is -SO3Na; n is equal to 2 to 6; when R is -CH3, the compound represented by the structural general formula is an oligomannuronicacid methyl acetate sulfate sodium salt; and when R is -CH2-CH(OH)-CH3, the compound represented by the structural general formula is an oligomannuronicacid proply acetate sulfate sodium salt. The medicament for intravenous injection has obvious anticoagulation, wherein the anticoagulation titer is 17 to 23; rabbit collagen induced platelet aggregation and platelet adhesion are obviously inhibited; and local ischemic brain damage caused by formation of cerebral thrombosis is lessened by inhibiting the formation of cerebral thrombosis and ischemic brain tissues are obviously protected.

The invention discloses a alginate lyase (Alg509) derived from marine bacteria and its gene. At the same time, the method for recombinant expression and preparation of the alginate lyase is also disclosed, which is about to alg509 The gene is cloned into an Escherichia coli expression vector, and the vector is transformed into an Escherichia coli host bacterium to obtain a recombinant engineering strain capable of heterologously expressing the enzyme. The alginate lyase Alg509 disclosed by the present invention has high enzyme activity, the specific enzyme activity can reach more than 48000U / mg, the optimum reaction pH is 10, the optimum reaction temperature is 55°C, and the enzyme activity has no dependence on various metal ions . The enzyme is active on sodium alginate, polyguluronic acid (polyG) and polymannuronic acid (polyM), and can completely degrade sodium alginate to produce fucobiose, fucoidanose, and fucoidan Sugar and other fucoidan oligosaccharides. The enzyme exhibits strong basophilicity, has a certain tolerance to high pH, ​​has a certain potential for industrial application, and can be widely used in agriculture, food, feed additives, medicine and other fields.